-
Human CD19+ B Cells (10 Million Cells, Positive Selection)Catalog #: 4W-600
Human CD19+ B cells isolated from peripheral blood using positive immunomagnetic selection, cryopreserved, ≥10 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Sales unit: each -
Human CD19+ B Cells, 10 Million Cells, Positive SelectionCatalog #: 2W-600
Human CD19+ B cells isolated from peripheral blood using positive immunomagnetic selection, cryopreserved, ≥10 million cells
Sales unit: Ampule -
Human Bone Marrow, CD34+ Depleted, MNC, 100MCatalog #: 4M-105all CD34 isolation are done by using Indirect Isolation kitsSales unit: each
-
Human CD14+ Monocytes (From Mobilized Blood, 25 Million Cells)Catalog #: 4Y-125
Human CD14+ monocytes, isolated from mobilized peripheral blood using positive immunomagnetic selection, ≥ 25 million cells, cryopreserved
Please note: This product will be discontinued once stock is depleted
Sales unit: each -
Human CD14+ Monocytes (From Mobilized Blood, 10 Million Cells)Catalog #: 4Y-125A
Human CD14+ monocytes, isolated from mobilized peripheral blood using positive immunomagnetic selection, ≥ 10 million cells, cryopreserved
Please note: This product will be discontinued once stock is depleted
Sales unit: each -
Human CD19+ B Cells (10 Million Cells, Negative Selection)Catalog #: 4W-601
Human CD19+ B cells isolated from peripheral blood using negative immunomagnetic selection, cryopreserved, ≥10 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Sales unit: each -
Human CD19+ B Cells (10 Million Cells, Negative Selection)Catalog #: 2W-601
Human CD19+ B cells isolated from peripheral blood using negative immunomagnetic selection, cryopreserved, ≥10 million cells
Sales unit: Ampule -
Human Naïve CD8+/CD45RA+ T CellsCatalog #: 4W-302Human CD8+/CD45RA+ naïve cytotoxic T cells, isolated from peripheral blood using negative immunomagnetic selection, ≥ 5 million cells, cryopreservedSales unit: each
-
Human CD4+/CD45RA+ Naive T CellsCatalog #: 4W-202Human CD4+/CD45RA+ Naive T cells, isolated from peripheral blood using negative immunomagnetic selection, ≥ 5 million cells, cryopreservedSales unit: each
-
Human Peripheral Blood CD3+ Pan T Cells, Cryopreserved, 25 MillionCatalog #: 2W-350
Human CD3+ T cells, isolated from peripheral blood using negative immunomagnetic selection, ≥ 25 million cells, cryopreserved
Sales unit: Ampule
-
Cryopreserved Human LeukopakA brief guide and introduction to Lonza Cryopreserved Leukopak
-
Custom Human Immune Cell Isolations Toss SheetA brief introduction to the services that Lonza CellBio Service can offer with regards to custom immune cell isolations.
-
Instructions - Cryopreserved Human Stellate CellsTechnical Instructions for culturing human stellate cells
-
Discover the Freshness of Frozen PBMCsAn Assessment of Cryopreservation Impact on T Cell Activation
-
Human CD34+ Cells Technical information and instructions for use
-
Cold Storage of Fresh Leukopak Maintains Cell Viability and FunctionalityLearn how advanced cold storage approaches enable optimal levels of product integrity, quality, stability and viability
-
Primary Blood and Immune Cells for ResearchPresentation (PDF) showcasing Lonza's portfolio and capabilities of primary blood and immune cells for research.
-
Cryopreservation of Peripheral Blood Mononuclear CellsDoes Not Alter Immune Cell Phenotype
-
The Cell and Gene Therapies Journey from Translation to CommercializationDownload our comprehensive eBook on how to accelerate cell and gene therapy development, from translation to GMP production and commercialization.
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.